glp-1 and afib Drugs May Have Role in Secondary Prevention of AF How should clinicians choose between

Insurance coverage varies depending on your individual plan and the medication prescribed

Langerhans noticed an island of cells in a rabbit pancreas stained differently from the surrounding tissue

Suicidality among users of glucagon-like peptide-1 receptor agonists: an emerging signal

Carmin, who also lives in Denver, said she was teased about her weight as a child and has had six 150lb weight swings in her life

Wegovy is licensed in the UK in doses up to 2.4mg for weight loss and, on 14 September 2025, Novo Nordisk published results of a phase IIIb clinical trial (STEP UP, NCT05646706) of a 7.2mg dose of semaglutide for subcutaneous injection 1